Literature DB >> 8346978

Small intestinal bacterial overgrowth in patients with rheumatoid arthritis.

A E Henriksson1, L Blomquist, C E Nord, T Midtvedt, A Uribe.   

Abstract

OBJECTIVES: To examine the microflora of the upper small intestine in patients with seropositive rheumatoid arthritis (RA) using a combination of microbial cultivation and tests for microbial metabolic activity.
METHODS: Twenty five patients with seropositive RA, 12 achlorhydric control subjects, and 11 control subjects with normal gastric acid secretion were investigated. Disease activity was evaluated in the patients with RA by three different indices. Eight (32%) of the patients with RA had hypochlorhydria or achlorhydria. The acid secretory capacity was determined with pentagastrin stimulation. A modified Crosby capsule was used to obtain biopsy specimens and samples of intestinal fluid from the proximal jejunum; aerobic and anaerobic microbial cultivation of mucosal specimens/intestinal fluid was carried out, and gas production and microflora associated characteristics in jejunal fluid were determined. Additionally, a bile acid deconjugation breath test was performed.
RESULTS: Subjects with at least one of the following findings were considered to have bacterial overgrowth: positive bile acid deconjugation test; growth of Enterobacteriaceae; positive gas production; or low tryptic activity. By these criteria half of the patients with RA with hypochlorhydria or achlorhydria and half of the achlorhydric controls had bacterial overgrowth. Thirty five per cent of the patients with RA with normal gastric acid secretion had bacterial overgrowth compared with none of the normal controls. Disease activity indices and rheumatoid factor titres were significantly higher in patients with RA with bacterial overgrowth than in those without.
CONCLUSIONS: A high frequency of small intestinal bacterial overgrowth was found in patients with RA; it was associated with a high disease activity and observed in patients with hypochlorhydria or achlorhydria and in those with normal acid secretion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346978      PMCID: PMC1005088          DOI: 10.1136/ard.52.7.503

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  46 in total

1.  Arthritis and enteritis--an interface of protean manifestations.

Authors:  R D Inman
Journal:  J Rheumatol       Date:  1987-06       Impact factor: 4.666

Review 2.  Causes of arthritis.

Authors:  D A Brewerton
Journal:  Lancet       Date:  1988-11-05       Impact factor: 79.321

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

Review 4.  Intestinal bacteria and rheumatic disease.

Authors:  T Midtvedt
Journal:  Scand J Rheumatol Suppl       Date:  1987

5.  Gastrin, gastric acid secretion, and gastric microflora in patients with rheumatoid arthritis.

Authors:  K Henriksson; K Uvnäs-Moberg; C E Nord; C Johansson; R Gullberg
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

6.  Cell proliferation of the rat gastrointestinal mucosa after treatment with E2 prostaglandins and indomethacin.

Authors:  A Uribe; C Johansson; C Rubio
Journal:  Digestion       Date:  1987       Impact factor: 3.216

7.  Development of five metabolic activities associated with the intestinal microflora of healthy infants.

Authors:  A C Midtvedt; B Carlstedt-Duke; K E Norin; H Saxerholt; T Midtvedt
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988 Jul-Aug       Impact factor: 2.839

8.  Effects of prostaglandin E2 on disease activity, gastric secretion and intestinal permeability, and morphology in patients with rheumatoid arthritis.

Authors:  A E Henriksson; C Tagesson; A Uribe; K Uvnäs-Moberg; C E Nord; R Gullberg; C Johansson
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

9.  Clinical and genetic characteristics of upper gastrointestinal disease in rheumatoid arthritis.

Authors:  E L Semble; R A Turner; W C Wu
Journal:  J Rheumatol       Date:  1987-08       Impact factor: 4.666

10.  Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans.

Authors:  I Bjarnason; G Zanelli; T Smith; P Prouse; P Williams; P Smethurst; G Delacey; M J Gumpel; A J Levi
Journal:  Gastroenterology       Date:  1987-09       Impact factor: 22.682

View more
  6 in total

Review 1.  A systematic review of diagnostic tests for small intestinal bacterial overgrowth.

Authors:  Reza Khoshini; Sun-Chuan Dai; Sheila Lezcano; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

2.  Arthritis as the presenting symptom of diverticulitis.

Authors:  D Schapira; A Nachtigal; Y Scharf
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

3.  Enhanced jejunal production of antibodies to Klebsiella and other Enterobacteria in patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  O Mäki-Ikola; R Hällgren; L Kanerud; N Feltelius; L Knutsson; K Granfors
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

4.  Small intestinal bacterial overgrowth in patients with rheumatoid arthritis.

Authors:  S J Lewis
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

5.  Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation.

Authors:  Widian K Jubair; Jason D Hendrickson; Erin L Severs; Hanna M Schulz; Sumitra Adhikari; Diana Ir; Jose D Pagan; Robert M Anthony; Charles E Robertson; Daniel N Frank; Nirmal K Banda; Kristine A Kuhn
Journal:  Arthritis Rheumatol       Date:  2018-07-02       Impact factor: 10.995

Review 6.  Gastrointestinal and hepatic manifestations of rheumatoid arthritis.

Authors:  Ellen C Ebert; Klaus D Hagspiel
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.